×
Zai Lab Common Stock Net 2016-2025 | ZLAB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Zai Lab common stock net from 2016 to 2025. Common stock net can be defined as the value of common equity ownership.
View More
Zai Lab Common Stock Net 2016-2025 | ZLAB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Zai Lab common stock net from 2016 to 2025. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$229.3B
Amgen (AMGN)
$159.6B
Gilead Sciences (GILD)
$140.8B
Vertex Pharmaceuticals (VRTX)
$118.7B
Bristol Myers Squibb (BMY)
$90B
CSL (CSLLY)
$82.4B
GSK (GSK)
$76.6B
Regeneron Pharmaceuticals (REGN)
$60.3B
Alnylam Pharmaceuticals (ALNY)
$52.7B
Argenex SE (ARGX)
$41.2B
BioNTech SE (BNTX)
$25.8B
Royalty Pharma (RPRX)
$20.9B
Insmed (INSM)
$20.6B
Biogen (BIIB)
$19.3B
Illumina (ILMN)
$15B
Incyte (INCY)
$14.8B
Genmab (GNMSF)
$14.7B
Genmab (GMAB)
$14B
BioMarin Pharmaceutical (BMRN)
$11.1B
QIAGEN (QGEN)
$11.1B
Moderna (MRNA)
$10.7B
Ascendis Pharma (ASND)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Exelixis (EXEL)
$10B
Exact Sciences (EXAS)
$9B
Verona Pharma American Depositary Share (VRNA)
$9B
Bio-Techne Corp (TECH)
$8.6B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$7.7B
Halozyme Therapeutics (HALO)
$7.3B